Business Update Neutral

2026-05-19 14:09

Piramal Pharma Limited informed about a schedule of analyst/institutional investor meetings to be held from May 28, 2026, to June 12, 2026. The company will engage with several financial institutions, including 360 ONE Capital, Bank of America, Citi India, ICICI Securities, and Goldman Sachs, through group or one-on-one meetings/investor conferences in Mumbai.

Business Update Positive

2026-05-18 11:46

Piramal Pharma Limited announced the successful closure of the US FDA inspection at its manufacturing facility in Digwal, Telangana, India. The US FDA has issued an Establishment Inspection Report (EIR), confirming the successful completion of the inspection that was previously intimated on February 14, 2026. This positive outcome ensures continued regulatory compliance for the facility.

Business Update Negative

2026-05-10 22:27

CRITICAL RED FLAG DETECTED

Piramal Pharma Limited's Sellersville (USA) facility underwent a US FDA GMP inspection from May 4-8, 2026. The inspection concluded with the issuance of a Form-483 citing three observations, which were recommended to be classified as Voluntary Action Indicated (VAI) and did not relate to data integrity. The company is preparing a detailed response to address the observations.

Routine Neutral

2026-05-04 15:22

New Filing detected. See link for details.

Routine Neutral

2026-04-30 14:48

New Filing detected. See link for details.

Routine Neutral

2026-04-29 16:52

Piramal Pharma Limited filed the contact details of its Key Managerial Personnel (KMP) as required by Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, on April 29, 2026. The KMPs listed are Mr. Vivek Valsaraj (CFO) and Mr. Maneesh Sharma (Company Secretary and Compliance Officer), with their respective email IDs, for materiality determination and disclosures.

Business Update Neutral

2026-04-29 16:46

Piramal Pharma Limited announced the availability of the audio recording of its conference call held on April 29, 2026. The call discussed the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2026. The recording is available on the company's website at https://www.piramalpharma.com/financial-reports.

Business Update Neutral

2026-04-29 16:33

Piramal Pharma Limited announced on January 29, 2026, the availability of the audio recording for its conference call held on April 29, 2026. The call discussed the audited financial results (Standalone and Consolidated) for the quarter and year ended March 31, 2026, and the recording can be accessed on the company's website.

Governance Positive

2026-04-28 21:27

Piramal Pharma's Board met on April 28, 2026, approving Audited Financial Results for Q4 and FY26 with an unmodified audit opinion. The Board re-appointed Ms. Nandini Piramal as Whole-Time Director & Chairperson for 3 years, Mr. Peter DeYoung as Whole-Time Director for 3 years, and Independent Directors Mr. Sridhar Gorthi and Mr. Peter Stevenson for 5 years each. Mr. Maneesh Sharma was appointed as Company Secretary and Compliance Officer, replacing Ms. Pratibha Mishra. The registered office address was also changed.

Governance Neutral

2026-04-28 21:24

Piramal Pharma Limited's Board of Directors approved the audited financial results for the quarter and financial year ended March 31, 2026, with statutory auditors issuing an unmodified opinion. The Board also approved the re-appointment of Ms. Nandini Piramal as Whole-Time Director (Executive Director and Chairperson) and Mr. Peter DeYoung as Whole-Time Director (Executive Director), each for a period of three years. Mr. Sridhar Gorthi and Mr. Peter Stevenson were re-appointed as Non-Executive, Independent Directors for five-year terms. Mr. Maneesh Sharma was appointed as Company Secretary and Compliance Officer, replacing Ms. Pratibha Mishra. A minor change in the registered office address was also approved.

Governance Neutral

2026-04-28 21:24

The Board of Directors of Piramal Pharma Limited, in a meeting on April 28, 2026, approved the Audited Financial Results (Standalone & Consolidated) for Q4 and the financial year ended March 31, 2026, which received an unmodified opinion. The board re-appointed Ms. Nandini Piramal (Chairperson & Executive Director) and Mr. Peter DeYoung (Executive Director) for three years. Mr. Sridhar Gorthi and Mr. Peter Stevenson were re-appointed as Non-Executive, Independent Directors for five years. Additionally, Mr. Maneesh Sharma was appointed as Company Secretary and Compliance Officer, and the registered office address was changed.

Governance Positive

2026-04-28 21:22

Piramal Pharma Limited's Board met on April 28, 2026, to approve the Audited Financial Results for Q4 and FY26, which received an unmodified opinion from the Statutory Auditors. The Board also approved the re-appointment of Ms. Nandini Piramal as Executive Director and Chairperson for three years, and Mr. Peter DeYoung as Executive Director for three years. Mr. Sridhar Gorthi and Mr. Peter Stevenson were re-appointed as Independent Directors for five years each. Additionally, Mr. Maneesh Sharma was appointed as the Company Secretary and Compliance Officer, and the registered office address was changed.

Financials Negative

2026-04-28 21:20

Piramal Pharma Limited reported flat Consolidated Revenue from Operations at ₹2,752Cr vs ₹2,754Cr (▲(0)% YoY) for Q4FY26. EBITDA decreased to ₹507Cr vs ₹603Cr (▼16% YoY). The company reported a net loss of ₹9Cr for the quarter, compared to a profit of ₹154Cr in the previous year, primarily due to an exceptional impairment loss of ₹176Cr. EBITDA Margin contracted from 22% to 18% (▼400bps). Management stated FY26 was a transitional year but expects accelerated growth in FY27.

Governance Neutral

2026-04-28 21:16

Piramal Pharma Limited's Board, on April 28, 2026, approved the Audited Financial Results for Q4 and FY26 with an unmodified opinion. Key governance decisions included the re-appointment of Ms. Nandini Piramal as Whole-Time Director and Chairperson, Mr. Peter DeYoung as Whole-Time Director, and Mr. Sridhar Gorthi and Mr. Peter Stevenson as Independent Directors for further terms. Additionally, Mr. Maneesh Sharma was appointed as Company Secretary and Compliance Officer, and a change in the registered office address was approved.

Governance Positive

2026-04-28 21:14

Piramal Pharma Limited's Board approved the Audited Financial Results for the quarter and financial year ended March 31, 2026, along with a declaration of an unmodified auditor's opinion. The Board also approved the re-appointment of Ms. Nandini Piramal as Whole-Time Director and Chairperson for three years, and Mr. Peter DeYoung as Whole-Time Director for three years. Mr. Sridhar Gorthi and Mr. Peter Stevenson were re-appointed as Non-Executive, Independent Directors for five years. Mr. Maneesh Sharma was appointed as the new Company Secretary and Compliance Officer.

Financials Negative

2026-04-28 21:12

Piramal Pharma Limited reported Audited Standalone Financial Results for the quarter ended March 31, 2026. Standalone Revenue was ₹1,489.06 Cr vs ₹1,689.80 Cr (▼12% YoY), EBITDA was ₹237.78 Cr vs ₹416.58 Cr (▼43% YoY), and PAT was ₹261.63 Cr vs ₹277.27 Cr (▼6% YoY). EBITDA Margin was 16.0% vs 24.7% (▼870 bps). Additionally, the Board approved the re-appointment of Ms. Nandini Piramal and Mr. Peter DeYoung as Whole-Time Directors, and Mr. Sridhar Gorthi and Mr. Peter Stevenson as Non-Executive, Independent Directors. Mr. Maneesh Sharma was appointed as Company Secretary and Compliance Officer.

Financials Neutral

2026-04-17 14:34

Piramal Pharma Limited announced it will host an investor/analyst conference call on April 29, 2026, from 9:30 AM IST to discuss its Q4 and full-year FY2026 financial results.

Business Update Positive

2026-04-13 10:25

Piramal Pharma Limited announced the successful closure of the US FDA inspection at its manufacturing facility in Lexington, USA. The US FDA has issued an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI), marking the successful completion of the inspection.

Business Update Positive

2026-04-06 18:35

Piramal Pharma Limited received an improved ESG Rating of 64 for FY 2024-25 from NSE Sustainability, up from 61 previously. This reflects the company's ongoing commitment to sustainability and responsible operations, as per the disclosure on April 6, 2026.

Business Update Positive

2026-04-01 16:26

Piramal Pharma's subsidiary successfully completed the acquisition of Kenalog® and its brands from Bristol-Myers Squibb Company. This strengthens its Complex Hospital Generics portfolio and expands presence in key markets like US, Europe, and Asia Pacific.

Business Update Neutral

2026-03-20 20:29

Piramal Pharma Limited disclosed that SES ESG Research Pvt. Ltd. assigned an ESG Rating of '68.5' for FY 2024-25, based on public domain data. The company clarified it had not engaged SES ESG for this voluntarily prepared report.

Business Update Neutral

2026-03-02 15:27

Piramal Pharma Limited informed about a scheduled analyst/institutional investor meeting on 9th March, 2026, with Investec India Promoter & Founder Conference 2026. The in-person meeting will be held in Mumbai.

Routine Neutral

2026-02-24 17:07

Piramal Pharma Limited filed on February 24, 2026, the contact details of its Key Managerial Personnel, Mr. Vivek Valsaraj (CFO) and Ms. Pratibha Mishra (Interim Company Secretary), as required under Regulation 30(5) of SEBI Listing Regulations.

Business Update Positive

2026-02-14 13:10

Piramal Pharma announced that the GPCB has granted an interim revocation of closure directions for its Dahej site, effective 13th February 2026. The company is now authorized to resume operations at the site.

Business Update Neutral

2026-02-14 12:58

US FDA conducted a GMP inspection of Piramal Pharma's Digwal facility (Feb 9-13, 2026), issuing Form-483 with 4 observations. These are procedural, not data integrity related, and classified as VAI (Voluntary Action Indicated). The company is preparing a response.

Business Update Negative

2026-02-11 18:43

CRITICAL RED FLAG DETECTED

Piramal Pharma informed of an interim environmental damage compensation of ₹1 crore imposed by GPCB on Feb 10, 2026, related to closure directions for its Dahej plant. The company is engaging with authorities for resolution.

Routine Neutral

2026-02-05 23:51

New Filing detected. See link for details.

Business Update Positive

2026-02-05 23:30

Piramal Critical Care (PCCI), an overseas subsidiary of Piramal Pharma Limited, announced a collaboration with Blue-Zone Technologies Ltd on February 5, 2026, to develop full lifecycle technology to capture, collect, and recycle waste anaesthetic gases, aiming to minimize environmental impact and produce Sevoflurane USP.

Business Update Neutral

2026-01-30 18:34

Piramal Pharma Limited announced on January 30, 2026, the availability of the transcript of its conference call held on January 29, 2026. The call discussed the unaudited financial results for the quarter and nine months ended December 31, 2025, accessible on their website.

PPLPHARMA

Piramal Pharma Limited

Filing History

Unlock Full History